
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is poised for financial growth driven by key momentum factors, including Medicare expansion and the anticipated positive outcomes from RCT data expected in 2026, which may lead to additional coverage wins that increase the number of covered lives. The company has also made significant strides with its product line, notably the G7 continuous glucose monitoring system, which offers improved sensor longevity and is anticipated to increase adoption rates, further supporting revenue growth. With operational efficiencies and margin improvements projected, DexCom is well-positioned to achieve mid-teens revenue growth along with over 20% EPS growth through 2028.
Bears say
DexCom's sensor revenue of $1.18 billion for the year showed a positive growth rate of 20% year-over-year; however, its hardware revenue experienced a significant decline of 31%, indicating challenges in product sales diversification. The company's forward guidance for fiscal year 2026 revenue of $5.16 billion to $5.25 billion represents a slower growth rate than anticipated, suggesting potential bearish sentiment among investors due to decelerating sales trends and shifts toward lower-margin pharmacy business. Furthermore, the expected sequential revenue decline of 6%-7% in Q1 2026 raises concerns regarding the sustainability of revenue growth and could lead to further downward pressure on DexCom's stock price as sales estimates are likely to be revised lower.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares